The Bob Harrington Show - Episode 36: Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone

Summary: The key to improved efficacy of antiplatelet regimens—in theory, at least—appears to be a personalized approach to therapy. But based on the TRIGGER-PCI and GRAVITAS trials, how productive is routine testing for platelet responsiveness in clinical practice? Dr Gregg Stone discusses his expertise in this field, why the hypothesis for TRIGGER-PCI did not work, his thoughts on the current role of genotype/phenotype testing, and why we should be optimistic about future research in this arena.